ASXL1 mutations in idiopathic cytopenias: determined significance?

被引：0
|
作者：
Galvez, Carlos [1 ]
Stein, Brady L. [2 ,3 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 03期
关键词：
CLONAL HEMATOPOIESIS; RISK; ICUS; MDS;
D O I：
10.1080/10428194.2018.1516880
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：568 / 570
页数：3
相关论文
共 50 条
  • [21] Analysis of ASXL1 Mutations in a Large Series of Myeloid Malignancies
    Van Ness, Michael
    Szankasi, Philippe
    Frizzell, Kimberly
    Shen, Wei
    Kelley, Todd W.
    LABORATORY INVESTIGATION, 2016, 96 : 381A - 381A
  • [22] Analysis of ASXL1 Mutations in a Large Series of Myeloid Malignancies
    Van Ness, Michael
    Szankasi, Philippe
    Frizzell, Kimberly
    Shen, Wei
    Kelley, Todd W.
    MODERN PATHOLOGY, 2016, 29 : 381A - 381A
  • [23] Prognostic significance of ASXL1 mutations in acute myeloid leukemia: A systematic review and meta-analysis
    Sheikhi, Maryam
    Rostami, Mehrdad
    Ferns, Gordon
    Ayatollahi, Hossein
    Siyadat, Payam
    Ayatollahi, Yasamin
    Khoshnegah, Zahra
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2024, 15 (02) : 202 - 214
  • [24] Mutations of ASXL1 and TET2 in aplastic anemia
    Huang, Jinbo
    Ge, Meili
    Lu, Shihong
    Shi, Jun
    Li, Xingxin
    Zhang, Jizhou
    Wang, Min
    Yu, Wei
    Shao, Yingqi
    Huang, Zhendong
    Zhang, Jing
    Nie, Neng
    Zheng, Yizhou
    HAEMATOLOGICA, 2015, 100 (05)
  • [25] ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?
    Hsu, Jingmei
    Kumar, Anita
    Carroll, Martin
    Frey, Noelle
    Shah, Nirav
    Zhao, Jianhua
    Hexner, Elizabeth
    Loren, Alison
    Perl, Alexander
    Porter, David
    Morrissette, Jennifer
    Luger, Selina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S195 - S195
  • [26] Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis
    Lin, Yun
    Zheng, Yi
    Wang, Ze-Chuan
    Wang, Shao-Yuan
    HEMATOLOGY, 2016, 21 (08) : 454 - 461
  • [27] ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?
    Hsu, Jingmei
    Kumar, Anita J.
    Carroll, Martin P.
    Frey, Noelle V.
    Shah, Nirav N.
    Jianhua, Zhao
    Hexner, Elizabeth O.
    Loren, Alison W.
    Mangan, James K.
    Perl, Alexander E.
    Porter, David
    Morrissette, Jennifer
    Luger, Selina M.
    BLOOD, 2014, 124 (21)
  • [28] Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs☆12 mutation
    Rotunno, Giada
    Mannarelli, Carmela
    Brogi, Giada
    Pacilli, Annalisa
    Gesullo, Francesca
    Mannelli, Francesco
    Fiaccabrino, Sara
    Sordi, Benedetta
    Paoli, Chiara
    Marone, Ilaria
    Rumi, Elisa
    Manfredini, Rossella
    Barosi, Giovanni
    Cazzola, Mario
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    BLOOD, 2019, 133 (26) : 2802 - 2808
  • [29] Prognostic Relevance of Truncating ASXL1 Mutations and ASXL1-Integrated Molecular Models in Proliferative CMML
    Csizmar, Clifford M.
    Gurney, Mark
    Lasho, Terra L.
    Kanagal-Shamanna, Rashmi
    Chien, Kelly S.
    Hammond, Danielle E.
    Finke, Christy M.
    Mangaonkar, Abhishek A.
    Al-Kali, Aref
    Gangat, Naseema
    Tefferi, Ayalew
    Alkhateeb, Hassan
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Patnaik, Mrinal M.
    BLOOD, 2023, 142
  • [30] ASXL1 MUTATIONS IN AML ARE ASSOCIATED WITH SPECIFIC CLINICAL AND CYTOGENETIC CHARACTERISTICS
    Kakosaiou, K.
    Panitsas, F.
    Ioannidou, A.
    Pagoni, M.
    Apostolou, P.
    Daraki, A.
    Vlachadami, I.
    Marinakis, T.
    Giatra, C.
    Vasilatou, D.
    Sambani, C.
    Pappa, V.
    Manola, K.
    HAEMATOLOGICA, 2017, 102 : 367 - 368
12345